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Policy Forum
T
he Grand Challenges in Global 
Health (GCGH) initiative is a 
major effort to achieve scientiﬁ  c 
breakthroughs against diseases that 
kill millions of people each year in 
the world’s poorest countries. With 44 
projects, more than US$450 million 
in funding, and scientists from 33 
countries, it has the potential to greatly 
reduce the suffering and death that 
disproportionately affect the 2 billion 
poorest people on earth. The 14 Grand 
Challenges serve seven long-term goals 
in global health [1], which are shown 
in Box 1.
Such a signiﬁ  cant investment 
in scientiﬁ  c research must be 
accompanied by a program addressing 
the ethical, social, and cultural (ESC) 
issues that may arise—either in the 
development and implementation of 
the research projects themselves, or 
in the subsequent appropriate use of 
resultant knowledge and technologies 
by communities in need (see next 
paper in this series by Berndtson et al. 
[2]).
Examples of setbacks as a result of 
ESC issues involving new technologies 
or approaches include: (1) the halting 
of trials of tenofovir (an antiviral 
medication used to treat HIV) in 
Cambodia, Cameroon, and Nigeria 
following claims there was not proper 
consultation with affected communities 
[3]; (2) rejection of white anti-malaria 
bed nets in cultures where that color 
was culturally sensitive [4]; and (3) 
Zambia’s rejection of genetically 
modiﬁ  ed foods because of perceived 
health, environmental, and economic 
risks [5].
The Bill & Melinda Gates 
Foundation has recognized the need 
to understand and address ESC issues 
in the GCGH initiative. In November 
2005, the foundation awarded us a 
grant to develop and run the ESC 
program for the GCGH. The two 
goals of the ESC program are (1) to 
provide an advisory service for GCGH 
projects on ethical, social, and cultural 
issues in the short- to mid-term, and 
(2) to create a research program to 
facilitate appropriate adoption of the 
technologies resulting from the GCGH 
projects in the long-term. Our starting 
assumptions for the ESC program are 
that science and technology play a key 
role in global health and development 
[6], and that the appropriate 
development and adoption of 
technology requires careful attention to 
the salient ethical, social, and cultural 
issues.
In this article we describe the ESC 
program of the GCGH initiative. We 
emphasize the features of our program 
that we believe represent valuable 
innovations in the evolution of ethical 
and social programs in large-scale 
science. We also introduce three 
subsequent articles appearing in this 
issue of PLoS Medicine that begin to 
illustrate some of the contributions of 
the ESC program to date [2,7,8].
What Is Already Known
To our knowledge, the ﬁ  rst large-scale 
science project to address ESC issues 
systematically was the Ethical, Legal and 
Social Implications (ELSI) program 
of the Human Genome Project. In 
1988, James Watson determined that 
3% of the project’s budget should be 
devoted to ELSI issues, raising this 
number to 5% in 1991 [9]. Although 
the ELSI program has stimulated 
efforts to inform the public about 
risks in genetic research and to deal 
with those concerns through research 
and education projects, a Science 
commentary on ELSI in 1996 revealed 
reservations about the program’s 
“blurry mandate” and distance from 
the applications of the actual science 
[9]. Watson himself suggested that he 
saw ELSI initially as a way merely to 
deﬂ  ect criticism from those wary of 
the consequences of genetic research, 
saying “It kept us from being attacked” 
[9]. An independent review of the ELSI 
research programs in 2000 criticized 
the limited number of voices informing 
ELSI research and recommended 
drawing on “theoretical perspectives 
from outside the traditional community 
of ELSI researchers” from a “broader 
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array” of disciplines and communities 
[10].
The Human Genome Project’s 
ELSI program set a standard for 
addressing ESC issues in large-scale 
science projects. Subsequent programs 
such as the International HapMap 
Project (http: ⁄⁄www.hapmap.
org/ethicalconcerns.html) and the 
National Nanotechnology Initiative 
(http: ⁄⁄www.nano.gov/html/society/
ELSI.html) have also adopted ESC 
programs. However, developing 
world involvement in these initiatives 
has been limited. For example, 
HapMap’s Populations/ELSI Group, 
which considers ethical and sampling 
issues in the HapMap project, links 
membership to funding. Although 
China has managed to secure ﬁ  nancial 
support, and therefore membership, 
Nigeria does not have the ﬁ  nancial 
means to join the group, whose 
other members include the United 
States, United Kingdom, Canada, and 
Japan [11]. All of the participants 
and contributors attending the 2003 
National Nanotechnology Initiative 
Workshop on societal implications 
of nanotechnology represented 
industrialized nations [12].
Our program aims to improve 
on previous programs by more 
successfully integrating the ESC 
activities with the scientiﬁ  c work 
of the GCGH investigators, and 
by focusing on ESC obstacles to 
the successful implementation of 
effective technologies for and with the 
developing world.
Preliminary Activities: Advisory 
Service
The goal of the advisory service is to 
facilitate the successful and appropriate 
achievement of milestones in the 
GCGH projects in the short- and mid-
term. Below we discuss the advisory 
service consultation model and give 
examples of two advisory service 
consults.
The ESC advisory service (Figure 
1) is designed to address ESC issues 
identiﬁ  ed at the outset of GCGH 
research projects, as well as challenges 
encountered as projects progress. At 
the GCGH kickoff meeting in Seattle 
in November 2005, we introduced the 
ESC advisory service to the project staff 
and to the GCGH program ofﬁ  cers. 
We explained that our goal was not to 
regulate research or to provide ethical 
cover. We recognized the expertise and 
accountability of the investigators and 
so did not see ourselves as providing a 
simple guidance function. Rather, our 
aim was to work in a close, integrated 
fashion with the investigators on ESC 
issues arising in their projects and thus 
contribute directly to the achievement 
of their milestones.
In the ﬁ  rst year of operation, we 
consulted with 24 of the 44 GCGH 
projects in varying levels of depth, from 
the achievement of speciﬁ  c regulatory 
and oversight milestones to preliminary 
discussions to scope out approaches 
to anticipated issues. The remaining 
20 projects have indicated no ESC 
advisory needs at this time, though we 
will continue to engage the project’s 
researchers to ensure any emerging 
ESC needs are met. Two in-depth 
consults (Boxes 2 and 3) illustrate 
the nature and scope of the advisory 
service and show responses and/or 
recommendations, as well as successes 
and lessons learned.
Based on our experience with 
the ﬁ  rst year of consults, we have 
Goal 1. Improve Childhood Vaccines
Grand Challenge #1: Create Effective 
Single-Dose Vaccines
Grand Challenge #2: Prepare Vaccines 
that Do Not Require Refrigeration
Grand Challenge #3: Develop Needle-
Free Vaccine Delivery Systems
Goal 2. Create New Vaccines
Grand Challenge #4: Devise Testing 
Systems for New Vaccines
Grand Challenge #5: Design Antigens for 
Protective Immunity
Grand Challenge #6: Learn about 
Immunological Responses 
Goal 3. Control Insects that Transmit 
Agents of Disease
Grand Challenge #7: Develop a Genetic 
Strategy to Control Insects
Grand Challenge #8: Develop a Chemical 
Strategy to Control Insects
Goal 4. Improve Nutrition to Promote 
Health 
Grand Challenge #9: Create a Nutrient-
Rich Staple Plant Species
Goal 5. Improve Drug Treatment of 
Infectious Diseases
Grand Challenge #10: Find Drugs 
and Delivery Systems that Limit Drug 
Resistance
Goal 6. Cure Latent and Chronic Infection
Grand Challenge #11: Create Therapies 
that Can Cure Latent Infection 
Grand Challenge #12: Create 
Immunological Methods to Cure Latent 
Infection
Goal 7. Measure Health Status 
Accurately and Economically in 
Developing Countries
Grand Challenge #13: Develop 
Technologies to Assess Population Health
Grand Challenge #14: Develop Versatile 
Diagnostic Tools
Box 1. Grand Challenges in Global Health
Figure 1. Consultation Model
The design of the ESC advisory service draws from a consultation model we have successfully used 
in the past. 
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implemented a plan to assign an 
advisory service co-leader (Jerome 
Singh or James Lavery) and a lead 
bioethicist (Paulina Tindana or Anant 
Bhan) to each GCGH project. In this 
way, ESC team members are developing 
Grand Challenge–speciﬁ  c expertise. To 
the extent possible, the assignment of 
the lead bioethicists reﬂ  ects their areas 
of training and expertise. During the 
initial phase of communication, the 
co-leader and lead bioethicist deﬁ  ne 
the issues and develop a preliminary 
strategy for addressing the consult.
In an attempt to stay ahead of 
emerging issues and consolidate our 
expertise for anticipated consults, 
we have also initiated a process of 
consultation with the GCGH program 
ofﬁ  cers. These relationships with the 
program ofﬁ  cers, who have extensive 
experience in the GCGH scientiﬁ  c 
areas, have been instrumental in 
helping us identify issues arising across 
Grand Challenges or within individual 
projects. In addition to occasionally 
inviting individual program ofﬁ  cers 
to join our bi-weekly advisory service 
conference calls, we have regular 
participation of program ofﬁ  cers in our 
bi-weekly full ESC team meetings, as 
well as occasional face-to-face meetings 
to discuss speciﬁ  c issues. These close 
working relationships have allowed 
us to beneﬁ  t from the expertise and 
insights of the program ofﬁ  cers in 
terms of understanding all of the 
relevant scientiﬁ  c dimensions of the 
projects, and to better appreciate and 
anticipate related ESC issues.
We have also developed a database of 
consults that documents the key issues, 
work plans, actions, and outcomes of 
each consult. This database serves as a 
detailed record of the advisory service 
activities, and is a key management tool 
in the evolution and evaluation of the 
advisory service.
Preliminary Activities: Research 
Program
The goal of the research program is 
to ﬁ  ll gaps in knowledge in order to 
facilitate the successful and appropriate 
adoption of the technologies 
resulting from the GCGH projects by 
communities in need in the long-term. 
The research program was designed to 
address cross-cutting issues in the GCGH 
projects. It has been shaped by a review 
of the project proposals, the results of 
the focus groups of GCGH investigators 
and program staff, and the survey of 
key informants in the developing world. 
Perhaps the most signiﬁ  cant question 
addressed by the research program 
is: Assuming some of the projects are 
successful and the technologies are 
developed, how will they reach the 
communities that need them in the 
developing world? Below we discuss four 
aspects of the research program that 
offer insight into that question.
Working papers. Some of the 
working papers we have drafted scope 
ESC issues in the GCGH. During the 
November 2005 GCGH meeting, we 
held focus groups with all the GCGH 
principal investigators as well as the 
program ofﬁ  cers for those grants, who 
are based at the Bill & Melinda Gates 
Foundation and the Foundation for the 
National Institutes of Health (which 
manages some of the GCGH projects), 
to seek their perspectives on the main 
ESC issues they expected to encounter 
in their GCGH projects. We then asked 
70 key informants from the developing 
world about these and other ESC 
issues in the GCGH. The results of this 
research are detailed in the second 
paper in this series in PLoS Medicine [2].
Given the importance the GCGH 
investigators and developing world 
key informants attached to community 
engagement as well as the role of 
civil society organizations, we have 
also prepared conceptual papers on 
these topics. These were distributed as 
working papers to GCGH investigators 
and program staff at the 2nd Annual 
GCGH Meeting, and the ﬁ  nal versions 
are published as the third and fourth 
articles in the series in this issue of 
PLoS Medicine [7,8]. In each article, we 
introduce the topic, brieﬂ  y review what 
is known, present some preliminary 
ﬁ  ndings from our program, and sketch 
next steps.
Another type of working paper 
generated through the ESC program 
arises from the unique and innovative 
nature of many of the GCGH projects 
in which the investigators face 
interesting and important ESC issues. 
As noted above, we provide guidance 
to investigators on these issues in the 
advisory service. However, many of 
these issues have not been adequately 
addressed in the literature. We believe 
our analyses and proposed solutions 
to important ESC challenges in the 
GCGH may be of use to the broader 
global health research community. 
The ﬁ  rst two of these advisory service 
articles document our approach to 
site selection for caged ﬁ  eld trials of 
genetically modiﬁ  ed mosquitoes, and 
Goal 3: Control Insects that Transmit 
Agents of Disease
Grand Challenge #7: Develop a Genetic 
Strategy to Control Insects
Nature and Scope of the Advisory 
Service Issue
Our ﬁ  rst in-depth consult started with 
a request for guidance in the selection 
of a ﬁ  eld site for caged ﬁ  eld trials of 
genetically modiﬁ  ed mosquitoes in four 
candidate countries: Thailand, Peru, 
Trinidad and Tobago, and Mexico.
Response/Recommendation Provided
In February 2006, the ESC advisory 
service conducted a site visit to Mexico 
to assess community and regulatory 
capacity for long-term engagement for 
caged ﬁ  eld trials of genetically modiﬁ  ed 
mosquitoes. This was followed in March 
2006 with a site visit to Trinidad for a 
similar assessment. We then worked 
closely with the investigators to guide 
the development of a framework of 
ESC considerations to facilitate the site 
selection decision. When Tapachula, 
Mexico was selected as the site of the 
caged ﬁ  eld trials, we began to work 
closely with the investigators and 
Mexican collaborators to develop the 
community engagement protocol for the 
project.
Successes and Lessons Learned
The project investigators used the 
ESC site selection framework to guide 
their ﬁ  nal decision. The framework 
ensured that the decision-making 
process was transparent, and involved 
a fully developed set of criteria and 
rationales. By their openness and highly 
collaborative approach to this aspect of 
their project, the project investigators 
also helped us demonstrate the value 
of deep integration of ESC issues with 
science. A description of the site selection 
experience has now been submitted for 
publication, and we hope it will prove 
useful for other researchers facing similar 
challenges, both within and beyond the 
GCGH. 
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our efforts to reconcile US and Chinese 
stem cell research guidelines to ensure 
adequate oversight of a GCGH-funded 
project involving stem cell research in 
China (Boxes 2 and 3). These articles 
will be published independently. We 
anticipate that in the next ﬁ  ve years of 
our program, we will produce about 20 
publications of this type.
Working groups. Our research has 
highlighted the importance of building 
ESC expertise on speciﬁ  c Grand 
Challenge goals, such as nutritionally 
enhanced foods, chemical and genetic 
control of insect populations, vaccines, 
and diagnostics. Each working group 
will be co-chaired by a developing 
world opinion leader and will include 
GCGH project investigators, program 
ofﬁ  cers, and members of our team. The 
groups will develop a technology road 
map leading from laboratory to village. 
They will identify and commission 
research to ﬁ  ll current gaps in 
knowledge on ESC issues and will 
identify actions needed to ensure the 
successful adoption of the technologies 
ﬂ  owing from GCGH projects.
Global case studies to identify 
good practices. Over the next three 
to four years, we propose to conduct 
two global case studies: one on 
community engagement, and one 
on commercialization of health 
technologies in low-resource settings. 
The goal of these projects is to identify 
a set of “good practices” related to 
these activities for developing world 
settings. We hope that the insights 
generated by these studies will assist the 
GCGH investigators and the broader 
global health research community.
Demonstration project on public 
engagement. We have developed 
and are beta-testing a media-rich 
web-based public engagement 
tool, WaterEngage, to function as a 
demonstration project meant to create 
a global virtual community of interest 
around global water problems (http: 
⁄⁄www.waterengage.com/). Among 
other things, the tool highlights 
how emerging nanotechnology and 
biotechnology applications can address 
waterborne and water-related diseases, 
e.g., through point of care diagnostics. 
We see a clear connection between the 
WaterEngage platform and the work of 
the GCGH program. We are currently 
developing MalariaEngage, a program 
which would create a virtual global 
community on this important topic. 
Ten of the 44 GCGH projects have 
potential relevance to malaria.
Next Steps
We believe that the ESC program is an 
innovative approach to dealing with key 
ethical issues in a large-scale science 
program that seeks to improve human 
well-being in the developing world. 
Our approach combines conceptual 
reﬂ  ection, empirical research, and 
service activities. It incorporates input 
from research programs, funders, and 
the broader community of potential 
beneﬁ  ciaries of research. The key 
features of this program, which may 
serve as a model for other large-scale 
science initiatives, are the close linkage 
of ESC activities to the science projects 
themselves, and the extensive inclusion 
of voices from the developing world.  
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Goal 2: Create New Vaccines
Grand Challenge #4: Devise Reliable Testing 
Systems for New Vaccines
Nature and Scope of the Advisory 
Service Issue
Focusing on human embryonic stem 
cell research in China, the challenge 
was to help the project meet a speciﬁ  c 
regulatory and oversight milestone. We 
did this by helping the team to establish 
an effective oversight mechanism for 
the project, and to help ensure that the 
project’s standard operating procedures 
and guidelines would be consistent 
with emerging standards in the United 
States, China, and elsewhere. The project 
required the development of a high-level 
regulatory ethics board (REB) and an 
embryonic stem cell research oversight 
committee to provide monitoring and 
ethical guidance.
Response/Recommendation Provided
The REB milestone of this project 
required four main outcomes:
1. The establishment of the REB, with 
membership including high-level 
representation of US and Chinese 
experts.
2. The development and adoption of a 
decision-making charter for the REB.
3. The development and adoption of 
standard operating procedures related 
to ethical and regulatory aspects of the 
project.
4. A customized training program on the 
operating procedures.
All of these requirements have now been 
met. The ESC advisory service served 
as an expert broker, facilitating the 
memberships of Prof. Jonathan Moreno, 
University of Pennsylvania (and member, 
Human Embryonic Stem Cell Research 
Advisory Committee, US National 
Academies) and Prof. Jeanne Loring, 
Burnham Institute, from the United 
States, and Prof. Xiaomei Zhai of Peking 
Union Medical College from China, on the 
REB and the oversight committee.
We also played an active role in the 
initial drafting and development of 
the REB decision-making charter, the 
main governance instrument for the 
REB. Standard operating procedures 
were developed to provide guidance 
to the researchers on the project. We 
participated in the ﬁ  rst training program 
for project research staff on regulatory 
and ethics issues, conducted in Beijing in 
July 2006.
Successes and Lessons Learned
This consult involved extensive 
deliberations and document drafting 
in collaboration with the US and 
Chinese experts, the project team, and 
the Bill & Melinda Gates Foundation 
program ofﬁ  cer. Key lessons learned 
were the importance of communication 
and relationship building for the 
establishment of trust and collaboration 
throughout the consult, and the 
importance of seeking outside expertise 
to supplement the advisory service. We 
expect this experience to be extremely 
valuable for future GCGH consults.
Box 3. Development of Novel Mouse Models for HIV and Hepatitis C 
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